Cargando…

Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis

OBJECTIVE: This review aimed to comprehensively analyze the safety and efficacy of erdafitinib in treating advanced and metastatic urothelial carcinoma and other solid tumors. METHODS: PubMed, Embase, and ClinicalTrials.gov were searched until 10 February 2022. The safety outcome as adverse events a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Xinyi, Wang, Hang, Deng, Junyue, Yao, Minghe, Zou, Xiuhe, Zhang, Fan, Ma, Xuelei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909824/ https://www.ncbi.nlm.nih.gov/pubmed/36776367 http://dx.doi.org/10.3389/fonc.2022.907377

Ejemplares similares

Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis
por: Rouvinov, Keren, et al.
Publicado: (2023)

Erdafitinib for locally advanced or metastatic urothelial carcinoma
por: Siefker-Radtke, Arlene O, et al.
Publicado: (2022)

Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma
por: Sayegh, Nicolas, et al.
Publicado: (2022)

Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells
por: Feng, Weiguo, et al.
Publicado: (2020)

Precision medicine: Sustained response to erdafitinib in FGFR2 ‐mutant, multiply recurrent ameloblastoma
por: Lawson‐Michod, Katherine A., et al.
Publicado: (2022)

Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor
por: Poon, Donald, et al.
Publicado: (2021)

Fibroblast Growth Factor Receptor 3 Amplified Metastatic Melanoma Treated With Erdafitinib
por: Sarkisian, Saro, et al.
Publicado: (2020)

BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
por: Kim, Se Hyun, et al.
Publicado: (2018)

Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma
por: Dosne, Anne-Gaëlle, et al.
Publicado: (2022)

Dramatic Responses of Recurrent Upper Urinary Tract Urothelial Carcinoma Harboring FGFR3 and TP53 Activating Mutations to Pembrolizumab in Combination with Erdafitinib: A Case Report
por: Ding, Xinjia, et al.
Publicado: (2021)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

Calciphylaxis associated with the fibroblast growth factor receptor inhibitor erdafitinib
por: Macklis, Paul, et al.
Publicado: (2020)

Comparison of Diagnostic Performance of Five Different Ultrasound TI-RADS Classification Guidelines for Thyroid Nodules
por: Yang, Ruoning, et al.
Publicado: (2020)

Successful Treatment and Retreatment With Erdafitinib for a Patient With FGFR3-TACC3 Fusion Squamous NSCLC: A Case Report
por: Pham, Chi, et al.
Publicado: (2023)

Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
por: Benjamin, David J, et al.
Publicado: (2022)

Radiosensitization by the Selective Pan-FGFR Inhibitor LY2874455
por: Darwis, Narisa Dewi Maulany, et al.
Publicado: (2022)

Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real-world evidence from an Expanded Access Program
por: Monteiro, Fernando Sabino M., et al.
Publicado: (2021)

Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer
por: Garje, Rohan, et al.
Publicado: (2020)

Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
por: Lima, Nadia Carvalho, et al.
Publicado: (2020)

Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors
por: Qu, Lingzhi, et al.
Publicado: (2022)

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
por: Papadopoulos, K P, et al.
Publicado: (2017)

PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020)

Severe onycholysis and eyelash trichomegaly in a patient treated with erdafitinib
por: Deutsch, Alana, et al.
Publicado: (2020)

Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation
por: Cao, Jian-zhou, et al.
Publicado: (2021)

Role of FGFR3 in Urothelial Carcinoma
por: Akanksha, Malik, et al.
Publicado: (2019)

ASP5878, a selective FGFR inhibitor, to treat FGFR3‐dependent urothelial cancer with or without chemoresistance
por: Kikuchi, Aya, et al.
Publicado: (2017)

Complexity of FGFR signalling in metastatic urothelial cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
por: Grünewald, Sylvia, et al.
Publicado: (2019)

TRLS-08. EXPERIENCE WITH THE SELECTIVE FIBROBLAST GROWTH FACTOR INHIBITOR ERDAFITINIB IN THREE PEDIATRIC PATIENTS WITH CNS TUMORS
por: Stepien, Natalia, et al.
Publicado: (2023)

The Effect of Posaconazole and Isavuconazole on the Pharmacokinetics of Erdafitinib in Beagle Dogs by UPLC-MS/MS
por: Ruan, Lan-hong, et al.
Publicado: (2021)

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines
por: Fumarola, Claudia, et al.
Publicado: (2019)

Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma
por: Hanes, Robert, et al.
Publicado: (2019)

Choroidal and Choriocapillaris Morphology in Pan-FGFR Inhibitor-Associated Retinopathy: A Case Report
por: Fasolino, Giuseppe, et al.
Publicado: (2022)

(18)F-labeled FGFR1 peptide: a new PET probe for subtype FGFR1 receptor imaging
por: Chen, Yang, et al.
Publicado: (2023)

Comparison Between Urothelial and Non-Urothelial Urethral Cancer
por: Wenzel, Mike, et al.
Publicado: (2021)

Erdafitinib’s effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer
por: Dosne, Anne‐Gaëlle, et al.
Publicado: (2021)

Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World Practice
por: Kuo, Ming-Chun, et al.
Publicado: (2020)

Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors
por: Lavoie, Jean-Michel, et al.
Publicado: (2021)

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder
por: Guancial, Elizabeth A, et al.
Publicado: (2014)

FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer
por: Kacew, Alec, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cjp2nnrpmnod0tdeamcog5cd45